Press Release Details

View all news

Quest Diagnostics Announces Sale of $225 Million In 1.75% Contingent Convertible Debentures Due 2021

11/19/1

TETERBORO, N.J., Nov. 19 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced today that it has sold to the public $225 million of 1.75% Contingent Convertible Debentures Due 2021. The debentures will pay a fixed rate of interest and are convertible into Quest Diagnostics common shares at an initial conversion price of $87.50 per share. The last reported sales price of Quest Diagnostics shares was $62.50 on November 16. The lead underwriter for the offering is Banc of America Securities LLC. Quest Diagnostics expects the transaction to be mildly accretive to 2002 earnings. Net proceeds from the offering will be used by the company to repay amounts outstanding under its receivables credit facility. The receivables credit facility will remain available to the company for general corporate purposes, including acquisitions.

The security is being offered as part of a shelf registration statement previously filed and declared effective with the Securities and Exchange Commission. Copies of the prospectus relating to the offering can be obtained from Banc of America Securities LLC, 9 West 57th Street, 40th Floor, New York, NY 10019.

Quest Diagnostics is the nation's leading provider of diagnostic testing, information and services with $3.4 billion in annual revenues. The company's diagnostic testing yields information that enables health care professionals and consumers to make better decisions to improve health. Quest Diagnostics offers patients and physicians the broadest access to diagnostic testing services through its national network of approximately 30 full-service laboratories, 150 rapid response laboratories and more than 1,300 patient service centers, where specimens are collected. Quest Diagnostics is the leading provider of esoteric testing, including gene-based testing, and is the leader in routine medical testing, drugs of abuse testing, and non-hospital-based anatomic pathology testing. Quest Diagnostics empowers health care organizations and clinicians with state-of-the-art connectivity solutions that improve practice management. Through partnerships with pharmaceutical, biotechnology and information technology companies, Quest Diagnostics provides support to help speed the development of health care insights and new therapeutics. Additional company information can be found on the Internet at: http://www.questdiagnostics.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the debentures, nor shall there be an offer to sell or a solicitation of an offer to buy the debentures in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such jurisdiction.

The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. Certain of these risks and uncertainties are listed in the Quest Diagnostics Incorporated 2000 Form 10-K and subsequent filings.

Contacts: Cathy Doherty (Investors): 201.393.5030,

                Gary Samuels (Media):  201.393.5700

SOURCE Quest Diagnostics Incorporated

CONTACT: Investors - Cathy Doherty, +1-201-393-5030, or Media - Gary Samuels, +1-201-393-5700, both of Quest Diagnostics/

Categories: Press Releases
View all news